• +1-646-491-9876
    • +91-20-67278686

    Search

    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

    • Report Code ID: RW0001499735
    • Category Pharmaceuticals
    • No. of Pages 75
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides an overview of the Dravet Syndrome (Central Nervous System) pipeline landscape.

    Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare and catastrophic form of intractable epilepsy that begins in infancy. Symptoms include ataxia (unsteadiness), sleep disturbance, and behavior problem.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dravet Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Dravet Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 2 and 1 respectively.Dravet Syndrome.

    Dravet Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Dravet Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dravet Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dravet Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dravet Syndrome (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dravet Syndrome (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dravet Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents

    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview 7
    Therapeutics Development 8
    Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview 8
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies 9
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance 10
    Late Stage Products 10
    Clinical Stage Products 11
    Early Stage Products 12
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies 13
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development 14
    Biscayne Pharmaceuticals Inc 14
    GW Pharmaceuticals Plc 15
    INSYS Therapeutics Inc 16
    OPKO Health Inc 17
    PTC Therapeutics Inc 18
    Sage Therapeutics Inc 19
    Xenon Pharmaceuticals Inc 20
    Zogenix Inc 21
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment 22
    Assessment by Monotherapy Products 22
    Assessment by Target 23
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Drug Profiles 31
    Antisense Oligonucleotide for Dravet Syndrome - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    ataluren - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    BIS-001 - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    cannabidiol - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    cannabidiol - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    CUR-1916 - Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    fenfluramine hydrochloride - Drug Profile 52
    Product Description 52
    Mechanism Of Action 52
    R&D Progress 52
    SAGE-217 - Drug Profile 55
    Product Description 55
    Mechanism Of Action 55
    R&D Progress 55
    Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 57
    Product Description 57
    Mechanism Of Action 57
    R&D Progress 57
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects 58
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones 59
    Featured News & Press Releases 59
    Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 59
    Oct 24, 2016: Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome 60
    Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs 61
    Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 62
    Jun 08, 2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference 64
    Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome 64
    May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 65
    Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 66
    Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 66
    Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 68
    Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 68
    Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 69
    Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome 69
    Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug 70
    Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 70
    Appendix 74
    Methodology 74
    Coverage 74
    Secondary Research 74
    Primary Research 74
    Expert Panel Validation 74
    Contact Us 74
    Disclaimer 75

    List of Tables

    Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Comparative Analysis by Late Stage Development, H2 2016 10
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Comparative Analysis by Early Stage Development, H2 2016 12
    Products under Development by Companies, H2 2016 13
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 14
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H2 2016 15
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics Inc, H2 2016 16
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health Inc, H2 2016 17
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics Inc, H2 2016 18
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics Inc, H2 2016 19
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc, H2 2016 20
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix Inc, H2 2016 21
    Assessment by Monotherapy Products, H2 2016 22
    Number of Products by Stage and Target, H2 2016 24
    Number of Products by Stage and Mechanism of Action, H2 2016 26
    Number of Products by Stage and Route of Administration, H2 2016 28
    Number of Products by Stage and Molecule Type, H2 2016 30
    Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H2 2016 58

    List of Figures

    Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Comparative Analysis by Early Stage Products, H2 2016 12
    Assessment by Monotherapy Products, H2 2016 22
    Number of Products by Targets, H2 2016 23
    Number of Products by Stage and Targets, H2 2016 23
    Number of Products by Mechanism of Actions, H2 2016 25
    Number of Products by Stage and Mechanism of Actions, H2 2016 25
    Number of Products by Routes of Administration, H2 2016 27
    Number of Products by Stage and Routes of Administration, H2 2016 27
    Number of Products by Molecule Types, H2 2016 29
    Number of Products by Stage and Molecule Types, H2 2016 29
    Biscayne Pharmaceuticals Inc
    GW Pharmaceuticals Plc
    INSYS Therapeutics Inc
    OPKO Health Inc
    PTC Therapeutics Inc
    Sage Therapeutics Inc
    Xenon Pharmaceuticals Inc
    Zogenix Inc

    Request for Sample

    Report Url http://www.reportsweb.com//dravet-syndrome-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//dravet-syndrome-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//dravet-syndrome-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments